Two covid-19 vaccines may be available in the Indian market early next year. According to Bernstein’s report, India has already confirmed the vaccine agreement for the leading race companies AstraZeneca and Novavax. In such a situation, vaccination can start in India as soon as the vaccine is approved.
According to the report, there are four potential vaccines globally, which are expected to be approved by the end of 2020 or early 2021. Two of these vaccines have been partnered by AstraZeneca and Oxford for the viral vector vaccine and Novavax’s protein subunit vaccine. The trials of these vaccines so far have proved successful in increasing immunity with standards. As such, an approved vaccine will become available in the market in the first quarter of 2021 in India.
She said that the cost of the vaccine could be three to six dollars (225 to 550 rupees) per dose. However, it may take up to two years for herd immunity to develop through vaccines. The reason for this is due to less knowledge of new viruses and less experience of vaccination. Initially vaccines will be made available to sensitive groups like health workers and people above 65 years of age etc. Vaccines can then be given to people engaged in essential services and poor people. India’s vaccine market could be worth six billion dollars in FY 2021-22.
Have to run polio like campaign
According to the report, India has two large-scale vaccination experiences. One was the 2011 polio eradication campaign and the other was the recent intensive Mission Indradhanush (IMI), but their level was one-third of what was required for the covid-19.
Vaccination campaign will take 18 to 20 months
Bernstein said that the chain of cold chain storage in vaccination and the lack of skilled labor are two major challenges. Even if their speed will be twice as much as before, it will still take 18 to 20 months for government vaccination to be implemented.
Serum preparing two billion doses
The Serum Institute of India is all set to introduce the first vaccine. Serum has tied up with AstraZeneca and Oxford and Novavax for their potential vaccine production. The serum is operating at an additional capacity of one billion doses. It is estimated that the institute will make 600 million doses in 2021 and one billion doses in 2022. Of these, 40 to 50 crore doses will be available for India in 2021. Three Indian companies, Zydus, Bharat Biotech and Biological e, are also working on their own vaccines. These vaccines are in Phase I and Phase II trials.